Aldevron

Partnerships like this don't happen overnight and they don't move forward without real alignment. At ASGCT, Emma Bjorgum (Aldevron) and Francesca Vitelli (Minaris Advanced Therapies) took a moment to share their excitement. This collaboration is about expanding access to lentiviral plasmids in a way that actually reduces complexity for developers. The goal is simple: make it easier to move from discovery into the clinic with greater consistency, fewer bottlenecks, and materials that are ready to scale when it matters most. #ASGCT #CellAndGeneTherapy #Biomanufacturing #LentiviralVectors

Ex-vivo LVV? In-Vivo LVV? This collaboration between Aldevron and Minaris Advanced Therapies gives our program sponsors access to Off-the-shelf material that is proven in clinical trials and best in class LVV titiers. Why spend the time and money optimizing your LVV packagers..? We have you covered - oh and custom GOI, in Reseach Grade through GMP, of course we have you covered there too! “A World where every cure is possible” - Aldevron

Moments like this highlight the importance of scalable, high-quality manufacturing in bringing breakthrough science to life. Honored that Aldevron teams could help accelerate such a meaningful advance. ---- Baby KJ was born with a rare, potentially fatal genetic disease with limited treatment options and significant uncertainty. In response, the world's first personalized CRISPR‑based therapy was designed, manufactured, and administered to him in record time. That effort is why teams from Children's Hospital of Philadelphia, Penn Medicine, University of Pennsylvania Health System, Innovative Genomics Institute, and Danaher Corporation received the ASGCT Catalyst Award this week at #ASGCT2026 . The work moved forward because people across medicine, academia, and industry stayed aligned on one outcome: turning a one‑of‑a‑kind scientific idea into a treatment for a child who needed it now. Doing that required coordination across research, manufacturing, and clinical care, with no precedent and no margin for delay. Danaher Life Sciences businesses Aldevron and Integrated DNA Technologies manufactured key components of this highly complex, personalized gene editing therapy at speed, with Aldevron producing the final drug product. Congratulations to the teams whose collaboration made this possible, and to the broader cell and gene therapy community advancing what can be delivered when expertise, scale, and urgency come together.

The announced partnership with Minaris below, is yet another example how Aldevron is uniquely positioned to support our program sponsors in a way no other CDMO is able, across multiple modalities and quality grades. With the Minaris partnership, Aldevron continues to support LVV / GMCT plasmid needs, from Discovery to Commercialization - No other CDMO has done more RG plasmid lots, and no one has more commercial products supported, outside Aldevron. “A world where every cure is possible” - Aldevron

Looking forward to connecting with all of you at ASGCT. I’m spending time at the Danaher booth (1337) alongside the Aldevron team. These conversations—across research, development, and manufacturing—are where real progress happens and impact is delivered at every stage. If you’re attending, feel free to stop by and say hello. 🔗 https://lnkd.in/ebXajcq2 #ASGCT #GeneTherapy #CellTherapy #ATMP #BiotechEvents

Early decisions in mRNA development have long‑term consequences. Join Aldevron for an upcoming webinar, Start Right. Scale Right: Scaling mRNA Therapeutics from Research‑Grade to cGMP, focused on the inflection points that can either accelerate progress or introduce comparability, regulatory, and scalability challenges. This session will explore: ✅Phase‑appropriate decisions for linear DNA templates, IVT, and analytics ✅Common scale‑up pitfalls such as variability, dsRNA formation, and material mismatches ✅How aligning research‑stage methods with cGMP realities can de‑risk tech transfer and clinical transitions Catch our webinar on May 20. Register now: https://ald.bio/4cvnIOX #mRNA #cGMP #GeneTherapy #Biomanufacturing #ProcessDevelopment

We are thrilled to renew Aldevron’s partnership with Minaris for access to lentiviral plasmids at any stage of development!

Translating non‑viral gene editing from concept to clinic requires more than strong design—it demands manufacturability, quality, and regulatory alignment from the start. In an upcoming Fierce Biotech webinar, Aldevron joins Integrated DNA Technologies to share a practical framework for advancing CRISPR‑based, non‑viral gene editing workflows from discovery through IND‑enabling stages. The discussion will explore how to: Design non‑viral CRISPR workflows that support both in vivo and ex vivo applications Account for manufacturability, quality, and traceability early to support clinical readiness Integrate analytical and regulatory expectations into a cohesive evidence package From Design to Delivery: A Translational Framework for Non‑Viral Gene Editing On April 21, 2026, at 11:00 a.m. ET Register here: https://ald.bio/41ygW65

Proud to see Aldevron recognized as a 2026 CDMO Leadership Award winner in Cell & Gene Therapy (Small & Mid-Sized). This honor reflects the deep expertise, collaboration, and commitment behind the teams supporting advanced therapeutic programs worldwide. Congratulations to everyone involved, and to all of the finalists and winners who continue to move the industry forward. ---- 𝗖𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗶𝗻𝗴 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝗰𝗲: 𝟮𝟬𝟮𝟲 𝗖𝗗𝗠𝗢 𝗼𝗳 𝘁𝗵𝗲 𝗬𝗲𝗮𝗿 𝗔𝘄𝗮𝗿𝗱𝘀 The 2026 CDMO Leadership Awards took place last night, highlighting the organizations setting the benchmark for innovation, expertise and collaboration across the global biopharma outsourcing landscape. This year's winners demonstrate the critical role CDMOs play in accelerating development and driving the industry forward. Congratulations to all of the finalists and a special mention to the winners below: 🏆 Large CDMO Winners Biologic: WuXi Biologics Cell & Gene Therapy: MilliporeSigma Small Molecule API: Lonza Finished Dose: Vetter Pharma Fill-Finish: AbbVie 🏆 Small & Mid-Sized CDMO Winners Biologic: Eurofins Cell & Gene Therapy: Aldevron Small Molecule API: Asymchem Group Finished Dose: Bend Bioscience Fill-Finish: KBI Biopharma A fantastic achievement across the board, driving partnership and progress. It was a very special evening and we had a fantastic time celebrating with you all! Orientation Marketing Life Science Connect